Discovery of dap-3 polymyxin analogues for the treatment of multidrug-resistant gram-negative nosocomial infections

Journal of Medicinal Chemistry

Volumn 56, Issue 12, 2013, Pages 5079-5093

  Magee, Thomas V ^a   Brown, Matthew F ^a   Starr, Jeremy T ^a   Ackley, David C ^a   Abramite, Joseph A ^a   Aubrecht, Jiri ^a   Butler, Andrew ^a   Crandon, Jared L ^b   Dib Hajj, Fadia ^a   Flanagan, Mark E ^a   Granskog, Karl ^a   Hardink, Joel R ^a   Huband, Michael D ^a,f   Irvine, Rebecca ^a   Kuhn, Michael ^a   Leach, Karen L ^a   Li, Bryan ^a   Lin, Jian ^a   Luke, David R ^a   Macvane, Shawn H ^b   Miller, Alita A ^a,f   McCurdy, Sandra ^a,g   McKim, James M ^c   Nicolau, David P ^b   Nguyen, Thuy Trinh ^a   Noe, Mark C ^a   O'Donnell, John P ^a,f   Seibel, Scott B ^a   Shen, Yue ^a   Stepan, Antonia F ^a   Tomaras, Andrew P ^a   Wilga, Paul C ^c   Zhang, Li ^d   Xu, Jinfeng ^e   Chen, Jinshan Michael ^a   more..

^a PFIZER INC   (United States)

^b HARTFORD HOSPITAL   (United States)

^c CeeTox Inc   (United States)

^d WUXI APPTEC   (China)

^e CPC Scientific   (China)

^f ASTRAZENECA   (United Kingdom)

^g CUBIST PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; DAB 3; DAP 3; POLYMYXIN B; POLYMYXIN DERIVATIVE; UNCLASSIFIED DRUG;

ACINETOBACTER BAUMANNII; ANIMAL EXPERIMENT; ANTIBACTERIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CELL DIFFERENTIATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG DESIGN; DRUG POTENCY; GRAM NEGATIVE BACTERIUM; HOSPITAL INFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CELL; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MULTIDRUG RESISTANCE; NEUTROPENIA; NONHUMAN; PHARMACODYNAMICS; PSEUDOMONAS AERUGINOSA; RAT;

ANIMALS; ANTI-BACTERIAL AGENTS; BETA-ALANINE; CROSS INFECTION; DOGS; DRUG DISCOVERY; DRUG RESISTANCE, MULTIPLE; FEMALE; GRAM-NEGATIVE BACTERIA; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; POLYMYXINS; RATS;

EID: 84879563263     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm400416u     Document Type: Article

References (62)

1. Maragakis, L. L. Recognition and prevention of multidrug-resistant Gram-negative bacteria in the intensive care unit Crit. Care Med. 2010, 38 (Suppl) S345-S351
2. Munoz-Price, L. S.; Weinstein, R. A. Acinetobacter Infection N. Engl. J. Med. 2008, 358, 1271-1281
3. Falagas, M. E.; Bliziotis, I. A. Pandrug-resistant Gram-negative bacteria: the dawn of the post-antibiotic era? Int. J. Antimicrob. Agents 2007, 29, 630-636
4. Gootz, T. D.; Marra, A. Acinetobacter baumannii: an emerging multidrug-resistant threat Expert Rev. Anti-Infect. Ther. 2008, 6, 309-325
5. Talbot, G. H. What is in the pipeline for Gram-negative pathogens? Expert Rev. Anti-Infect. Ther. 2008, 6, 39-49
6. Nation, R. L.; Li, J. Colistin in the 21st century Curr. Opin. Infect. Dis. 2009, 22, 535-543
7. Landman, D.; Georgescu, C.; Martin, D. A.; Quale, J. Polymyxins Revisited Clin. Microbiol. Rev. 2008, 449-465
8. Sarkar, S.; DeSantis, E. R. H.; Kuper, J. Resurgence of colistin use Am. J. Health-Syst. Pharm. 2007, 64, 2462-2466
9. Li, J.; Nation, R. L.; Turnidge, J. D.; Milne, R. W.; Coulthard, K.; Rayner, C. R.; Paterson, D. L. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections Lancet Infect. Dis. 2006, 6, 589-601
10. Yuan, Z.; Tam, V. H. Polymyxin B: a new strategy for multidrug-resistant Gram-negative organisms Expert Opin. Invest. Drugs 2008, 17, 661-668
11. Zavascki, A. P.; Goldani, L. Z.; Li, J.; Nation, R. L. Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review J. Antimicrob. Chemother. 2007, 60, 1206-1215
12. Benedict, R. G.; Langlykke, A. F. Antibiotic activity of Bacillus polymyxa J. Bacteriol. 1947, 54, 24-25
13. Ainsworth, G. C.; Brown, A. M.; Brownlee, G. 'Aerosporin', an antibiotic produced by Bacillus aerosporus Greer Nature 1947, 160, 263
14. Kang, J. W.; Van Schepdael, A.; Orwa, J. A.; Roets, E.; Hoogmartens, J. Analysis of polymyxin B sulfate by capillary zone electrophoresis with cyclodextrin as additive. Method development and validation J. Chromatogr. 2000, 879, 211-218
15. Orwa, J. A.; Govaerts, C.; Busson, R.; Roets, E.; Van Schepdael, A.; Hoogmartens, J. Isolation and Structural Characterization of Colistin Components J. Antibiot. 2001, 54, 595-599
16. Orwa, J. A.; Van Gerven, A.; Roets, E.; Hoogmartens, J. Development and Validation of a Liquid Chromatography Method for Analysis of Colistin Sulphate Chromatographia 2000, 51, 433-436
17. The prodrug is known as either colistimethate sodium, colistin methanesulfonate, or simply CMS. Each of the five γ amine nitrogens of the Dab residues at positions 1, 3, 5, 8, and 9 has a methanosulfonate moiety which decomposes in serum to the corresponding free base. See Gobin, P.; Lemaitre, F.; Marchand, S.; Couet, W.; Olivier, J.-C. Assay of colistin and colistin methanesulfonate in plasma and urine by liquid chromatography-tandem mass spectrometry Antimicrob. Agents Chemother. 2010, 54, 1941-1948
18. Molina, J.; Cordero, E.; Pachon, J. New information about the polymyxin/colistin class of antibiotics Expert Opin. Pharmacother. 2009, 10, 2811-2828
19. HsuChen, C.-C.; Feingold, D. S. The mechanism of polymyxin B action and selectivity toward biological membranes Biochem. 1973, 12, 2105-2111
20. Mares, J.; Kumaran, S.; Gobbo, M.; Zerbe, O. Interactions of lipopolysaccharide and polymyxin studied by NMR spectroscopy J. Biol. Chem. 2009, 284, 11498-11506
21. Srimal, S.; Surolia, N.; Balasubramanian, S.; Surolia, A. Titration calorimetric studies to elucidate the specificity of the interactions of polymyxin B with lipopolysaccharides and lipid A Biochem. J. 1996, 315, 679-686
22. Bruch, M. D.; Cajal, Y.; Koh, J. T.; Jain, M. K. Higher-order structure of polymyxin B: the functional significance J. Am. Chem. Soc. 1999, 121, 11993-12004
23. Bhattacharjya, S.; David, S. A.; Mathan, V. I.; Balaram, P. Polymyxin B nonapeptide: conformations in water and in lipopolysaccharide-bound state determined by two-dimensional NMR and molecular dynamics Biopolymers 1997, 41, 251-265
24. Pristovsek, P.; Kidric, J. Solution structure of polymyxins B and E and effect of binding to lipopolysaccharide: an NMR and molecular modeling study J. Med. Chem. 1999, 42, 4606-4613
25. Garidel, P.; Howe, J.; Brandenburg, K. Thermodynamic analysis of the interaction of lipopolysaccharides with cationic compounds Eng. Life Sci. 2008, 8, 523-529
26. Clausell, A.; Garcia-Subirats, M.; Pujol, M.; Busquets, M. A.; Rabanal, F.; Cajal, Y. Gram-negative outer and inner membrane models: insertion of cyclic cationic lipopeptides J. Phys. Chem. B 2007, 111, 551-563
27. Clausell, A.; Rabanal, F.; Garcia-Subirats, M.; Alsina, M. A.; Cajal, Y. Membrane association and contact formation by a synthetic analogue of polymyxin B and its fluorescent derivatives J. Phys. Chem. B 2006, 110, 4465-4471
28. Clausell, A.; Rabanal, F.; Garcia-Subirats, M.; Alsina, M. A.; Cajal, Y. Synthesis and membrane action of polymyxin B analogues Luminescence 2005, 20, 117-123
29. Clausell, A.; Busquets, M. A.; Pujol, M.; Alsina, A.; Cajal, Y. Polymyxin B-lipid interactions in Langmuir-Blodgett monolayers of Escherichia coli lipids: a thermodynamic and atomic force microscopy study Biopolymers 2004, 75, 480-490
30. Oh, J.-T.; Van Dyk, T. K.; Cajal, Y.; Dhurjati, P. S.; Sasser, M.; Jain, M. K. Osmotic stress in viable Escherichia coli as the basis for the antibiotic response by polymyxin B Biochem. Biophys. Res. Commun. 1998, 246, 619-623
31. Cajal, Y.; Rogers, J.; Berg, O. G.; Jain, M. K. Intermembrane molecular contacts by polymyxin B mediate exchange of phospholipids Biochemistry 1996, 35, 299-308
32. Cajal, Y.; Ghanta, J.; Easwaran, K.; Surolia, A.; Jain, M. K. Specificity for the exchange of phospholipids through polymyxin B mediated intermembrane molecular contacts Biochemistry 1996, 35, 5684-5695
33. Clausell, A.; Pujol, M.; Alsina, M. A.; Cajal, Y. Influence of polymyxins on the structural dynamics of Escherichia coli lipid membranes Talanta 2003, 60, 225-234
34. For an excellent review see: Velkov, T.; Thompson, P. E.; Nation, R. L.; Li, J. Structure-activity relationships of polymyxin antibiotics J. Med. Chem. 2010, 53, 1898-1916
35. Li, J.; Nation, R. L.; Turnidge, J. D.; Milne, R. W.; Coulthard, K.; Rayner, C. R.; Paterson, D. I. Colitsin: the re-emerging antibiotic for multi-drug resistant Gram-negative bacterial infections Lancet Infect. Dis. 2006, 6, 589-601
36. Falagas, M. E.; Rafailidis, P. I.; Matthaiou, D. K.; Virtzili, S.; Nikita, D.; Michalopoulos, A. Int. J. Antimicrob. Agents 2008, 32, 450-454
37. Falagas, M. E.; Kasiakou, S. K. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies Crit. Care 2006, 10, R27
38. Hartzell, J. D.; Neff, R.; Ake, J.; Howard, R.; Olson, S.; Paolino, K.; Vishnepolsky, M.; Weinrob, A.; Wortmann, G. Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center Clin. Infect. Dis. 2009, 48, 1724-1728
39. Kim, J.; Lee, K.-H.; Yoo, S.; Pai, H. Clinical characteristics and risk factors of colistin-induced nephrotoxicity Int. J. Antimicrob. Agents 2009, 34, 434-438
40. Ramasubban, S.; Majumdar, A.; Das, P. S. Safety and efficacy of polymyxin B in multidrug resistant Gram-negative severe sepsis and septic shock Indian J. Crit. Care Med. 2008, 12, 153-157
41. Mendes, C. A. C.; Cordeiro, J. A.; Burdmann, E. A. Prevalence and risk factors for acute kidney injury associated with parenteral polymyxin B use Ann. Pharmacother. 2009, 43, 1948-1955
42. Santamaria, C.; Mykietiuk, A.; Temporiti, E.; Stryjewski, M. E.; Herrera, F.; Bonvehi, P. Nephrotoxicity associated with the use of intravenous colistin Scand. J. Infect. Dis. 2009, 41, 767-769
43. Ouderkirk, J. P.; Nord, J. A.; Turett, G. S.; Kislak, J. W. Polymyxin B nephrotoxicity and efficacy against nosocomial infections caused by multiresistant Gram-negative bacteria Antimicrob. Agents Chemother. 2003, 47, 2659-2662
44. Falagas, M. E.; Rizos, M.; Bliziotis, I. A.; Rellos, K.; Kasiakou, S. K.; Michalopoulos, A. Toxicity after prolonged (more than four weeks) administration of intravenous colistin. BMC Infect. Dis. 2005, 5, DOI: 10.1186/1471-2334-5-1.
45. Ma, Z.; Wang, J.; Nation, R. L.; Li, J.; Turnidge, J. D.; Coulthard, K.; Milne, R. W. Renal disposition of colistin in the isolated perfused rat kidney Antimicrob. Agents Chemother. 2009, 53, 2857-2864
46. Vaara, M.; Vaara, T. Structure-activity studies on novel polymyxin derivatives that carry only three positive charges Peptides 2010, 31, 2318-2321
47. Vaara, M.; Siikanen, O.; Apajalahti, J.; Fox, J.; Frimodt-Moller, N.; He, H.; Poudyal, A.; Li, J.; Nation, R. L.; Vaara, T. A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane Antimicrob. Agents Chemother. 2010, 54, 3341-3346
48. Lundberg, C. V.; Vaara, T.; Frimodt-Moller, N.; Vaara, M. Novel polymyxin derivatives are effective in treating experimental Escherichia coli peritoneal infection in mice J. Antimicrob. Chemother. 2010, 65, 981-985
49. Vaara, M.; Vaara, T. Polymyxin derivatives and uses thereof. World Patent Application WO 2008/017734, 2008.
50. Vaara, M.; Fox, J.; Loidl, G.; Siikanen, O.; Apajalahti, J.; Hansen, F.; Frimodt-Moller, N.; Nagai, J.; Takano, M.; Vaara, T. Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents Antimicrob. Agents Chemother. 2008, 52, 3229-3236
51. O'Dowd, H.; Kim, B.; Margolis, P.; Wang, W.; Wu, C.; Lopez, S. L.; Blais, J. Preparation of tetra-Boc-protected polymyxin B nonapeptide Tetrahedron Lett. 2007, 48, 2003-2005
52. Viljanen, P.; Vaara, M. Susceptibility of Gram-Negative Bacteria to Polymyxin B Nonapeptide Antimicrob. Agents Chemother. 1984, 25, 701-705
53. Sato, Y.; Shindo, M.; Sakura, N.; Uchida, Y.; Kato, I. Novel des -fatty acyl-polymyxin B derivatives with Pseudomonas aeruginosa -specific antimicrobial activity Chem. Pharm. Bull. 2011, 59, 597-602
54. Leese, R. A. Antibiotic compositions for the treatment of Gram negative infections. United States Patent Application US 2010/0160215, 2010.
55. Li, J.; Velkov, T.; Nation, R. L.; Thompson, P. E. Antimicrobial compounds. World Patent Application WO 2010/130007, 2010.
56. Beceiro, A.; Llobet, E.; Aranda, J.; Bengoechea, J. A.; Doumith, M.; Hornsey, M.; Dhanji, H.; Chart, H.; Bou, G.; Livermore, D. M.; Woodford, N. Phosphoethanolamine Modification of Lipid A in Colistin-Resistant Variants of Acinetobacter baumannii Mediated by the pmrAB Two-Component Regulatory System Antimicrob. Agents Chemother. 2011, 55, 3370-3379
57. Moffatt, J. H.; Harper, M.; Adler, B.; Nation, R. L.; Li, J.; Boyce, J. D. Insertion Sequence IS Aba11 Is Involved in Colistin Resistance and Loss of Lipopolysaccharide in Acinetobacter baumannii Antimicrob. Agents Chemother. 2011, 55, 3022-3024
58. Lee, J.-Y.; Song, J.-H.; Ko, K. S. Identification of Nonclonal Pseudomonas aeruginosa Isolates with Reduced Colistin Susceptibility in Korea Microb. Drug Resist. 2011, 17, 299-304
59. Meredith, J. J.; Dufour, A.; Bruch, M. D. Comparison of the Structure and Dynamics of the Antibiotic Peptide Polymyxin B and the Inactive Nonapeptide in Aqueous Trifluoroethanol by NMR Spectroscopy J. Phys. Chem. B 2009, 113, 544-551
60. Kim, A.; Banevicius, M. A.; Nicolau, D. P. In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures Antimicrob. Agents Chemother. 2008, 52, 2497-2502
61. Chen, J. M.; Li, Z. B.; Magee, T. V.; Martinez, C. A. Polymyxin derivatives useful as antibacterial agents. PCT Int. Appl. WO2012168820, 2012
62. Chem. Abstr. 2012, 1819188.